Form 4: EXELIS EVP Sells Shares in Pre-Planned Transaction

Exelixis EVP of Research and Development, Dana Aftab, sold 47,918 shares of common stock for $44.5 per share in a pre-scheduled transaction.

Summary

• Dana Aftab, EVP of Research and Development at Exelixis, Inc. (EXEL), sold 47,918 shares of common stock.
• The transaction occurred on February 24, 2026, at a price of $44.5 per share.
• The sale was executed under a Rule 10b5-1(c) plan, indicating it was pre-scheduled.
• Following the transaction, Dana Aftab directly owns 616,106 shares, which includes 414,043 shares from restricted stock units (RSUs) and performance stock units (PSUs) vesting on March 31, 2025.
• Additionally, Dana Aftab indirectly owns 5,835 shares through the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated February 23, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because it is a pre-planned insider sale, which is a routine occurrence for executives managing their personal finances and not typically indicative of a change in company fundamentals.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, suggesting it was a pre-scheduled sale rather than a reaction to recent events or material non-public information.

Negatives

• A high-level executive sold a significant number of shares (47,918 shares), which some investors might interpret as a negative signal, despite being pre-planned.

Risks

• Insider selling, even if pre-planned under a 10b5-1 plan, can sometimes be perceived negatively by the market, potentially leading to short-term price volatility.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are routinely monitored by investors for signals about a company's internal health or future prospects. However, sales executed under a Rule 10b5-1 plan are generally viewed as less indicative of a negative outlook, as they are pre-arranged to avoid accusations of trading on material non-public information and are often part of an executive's long-term financial planning.

Comparison to Industry Standards

• Insider selling is a common occurrence across all industries, particularly among executives who receive a significant portion of their compensation in equity.
• For example, executives at other biotech and pharmaceutical companies, such as Amgen or Gilead Sciences, frequently utilize 10b5-1 plans for liquidity or portfolio diversification, making this transaction consistent with standard executive compensation and financial planning practices within the sector.

Stakeholder Impact

• Shareholders: May observe the insider sale, but the execution under a 10b5-1 plan generally mitigates concerns about the transaction signaling a negative outlook for the company.

Next Steps

• Vesting of 414,043 restricted stock units (RSUs) and performance stock units (PSUs) on March 31, 2025, which will be issued to Dana Aftab.

Key Dates

Recommendation

The insider sale by Dana Aftab, while significant in volume, was executed under a Rule 10b5-1 plan, indicating it was a pre-scheduled transaction for personal financial management rather than a reaction to new material information. This type of transaction is common for executives and does not inherently signal a change in the company's fundamental outlook or performance. Therefore, a 'hold' recommendation is appropriate as this specific filing does not provide new information to alter an existing investment thesis.

Keywords

Exelixis, EXEL, Insider Trading, Form 4, Stock Sale, Dana Aftab, EVP Research and Development, 10b5-1 Plan